Putting Patients First!

Make an Appointment (TF): (844) 215-0731

Refer Now (Fax): (888) 630-8885

69th Annual Post Graduate Assembly (PGA)

  October 21, 2015

Dr. Meraj Siddiqui is presenting his research during the scientific session of the 69th Annual Post Graduate Assembly (PGA) meeting of the New York Society of Anesthesiologists in New York. New York Society of Anesthesiologists is the oldest society of anesthesiologists in the world. It is also one of the most respected scientific forums for anesthesia and pain management. Top scientists from all over the world are expected to present their state of the art scientific research at the 69th PGA meeting.

Dr. Siddiqui has been involved in research for over 20 years. Over the years, he has presented research papers at many different world class conferences. He is one of the leading experts in chronic pain management. One of his research focus areas is the management of chronic pain via the administration of spinal or intrathecal medications through an implantable pump. An implantable drug delivery system (IDDS), commonly known as a morphine pump, can deliver a variety of medications directly into the spinal cord. This therapy is generally reserved as a last resort for treatment of chronic intractable pain that is not being managed with a high dose of opioids or other interventional therapies, including surgery. One of the challenges with initiating and maintaining pump therapy is how to safely convert an oral opioid dose into an intrathecal pump dose. If oral opioid medication is stopped abruptly at the time of pump therapy initiation, then the patient may go into severe withdrawals. On the other hand, if oral opioids continue with pump therapy, then there is an increased chance of opioid overdose, which could potentially be lethal.

The new generation of Medtronic’s implantable drug delivery system, the “Pump,” comes with a device called a Personal Therapy Manager (PTM) that allows patient to administer an additional fixed dose of intrathecal medication on preset intervals for breakthrough pain. The PTM plays an instrumental role in controlling breakthrough pain.

Dr. Siddiqui’s research evaluates the role of a PTM in preventing morphine withdrawals when converting from the use of oral to intrathecal morphine by an implantable drug delivery system. His study showed that with the use of a PTM, oral morphine can be stopped completely at the time that intrathecal morphine therapy is initiated via an IDDS without causing the patient to go into morphine withdrawals. This is the first study ever done to establish the role of a PTM in preventing morphine withdrawals when converting from oral to intrathecal morphine therapy.

Dr. Siddiqui is presenting his study on December 12, 2015 at the Marriott Marquis in New York City.

Recent Posts

Contact Us
Our Locations